Recent 8-K filings for CLRB

• July 10, 2026, 5:13 PM ET other material materiality 0.65 neutral item 5.02item 5.07item 9.01

  Cellectar shareholders approve warrant exercise for up to 39.6M shares, increase share reserve by 2M

  Class III directors Andrew Gu and Douglas J. Swirsky elected to three-year terms.

• May 14, 2026, 7:20 AM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Cellectar reports Q1 net loss $5.7M; positive iopofosine data, up to $140M financing

  Q1 net loss $5.7M ($1.33/share) vs $6.6M ($4.30/share) YoY; cash $8.3M at March 31.

• May 8, 2026, 7:59 PM ET other material materiality 0.80 positive item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements ×4

  Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data

  Gross proceeds ~$35M; issued 1.6M registered shares, 2.1M unregistered, and warrants for 9.5M+13.2M shares.

• March 4, 2026, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Cellectar Biosciences reports FY2025 net loss $21.8M, cash $13.2M; plans EMA submission Q3 2026

  Net loss $21.8M ($8.35/share) vs $44.6M ($36.52/share) in 2024; company pre-revenue.

• November 13, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Cellectar Q3 net loss $4.4M ($1.41/sh); cash $12.6M; progress on EU conditional marketing for iopofosine

  Net loss narrowed to $4.4M ($1.41/sh) from $14.7M ($11.18/sh) YoY; R&D spending fell to $2.5M.

• October 10, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01item 2.02item 3.02item 3.03item 8.01item 9.01

  Cellectar raises ~$5.8M via warrant exercise; prelim cash $12.6M as of Sep 30

  Gross proceeds of ~$5.8M from exercise of 1,048,094 existing warrants at $5.25/share; holders paid $0.125 per new warrant.

• October 6, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 7.01item 8.01item 9.01

  EMA confirms iopofosine I 131 eligible for Conditional Marketing Authorization in post-BTKi WM

  SAWP advised filing a CMA for iopofosine I 131 in post-BTKi refractory WM could be acceptable.

• August 14, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Cellectar to pursue accelerated NDA for iopofosine I 131 in WM; Q2 net loss $5.4M

  Plans NDA submission for accelerated approval of iopofosine I 131 in WM, subject to sufficient funding and confirmatory trial initiation.

• June 26, 2025, 7:59 PM ET other material materiality 0.65 neutral item 8.01

  Cellectar provides clinical updates, plans Phase 1 studies for CLR 125 and CLR 225 in H2 2025 subject to financing

  CLR 125 (Auger-emitting PRC) Phase 1b study in triple-negative breast cancer planned for H2 2025, subject to additional financing.

• May 13, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Cellectar Biosciences Q1 2025 Net Loss Narrowed to $6.6M; Seeks EMA Conditional Approval for Iopofosine

  Net loss for Q1 2025 was $6.6 million ($0.14 per share), compared to $26.6 million ($0.91 per share) in Q1 2024.

• May 1, 2025, 7:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Cellectar Biosciences to explore strategic alternatives; hires Oppenheimer as advisor

  Board authorized exploration of M&A, partnerships, licensing or other transactions; no deal reached.

• March 13, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Cellectar Biosciences FY2024 net loss $44.6M; FDA agrees on accelerated approval path for iopofosine I 131

  Net loss of $44.6M ($1.22 basic EPS) vs $42.8M in 2023; cash $23.3M as of Dec 31, 2024.

• January 31, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices ×2

  Cellectar receives Nasdaq minimum bid price deficiency notice; 180-day cure period until July 29, 2025

  Notice from Nasdaq on Jan 30, 2025 for failure to maintain $1.00 minimum bid price per Nasdaq Listing Rule 5550(a)(2).

• January 14, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Cellectar reports iopofosine 83.6% ORR in WM; plans confirmatory study for accelerated approval

  Iopofosine I 131 achieved 83.6% ORR and 58.2% MRR in Phase 2 CLOVER-WaM for Waldenstrom's Macroglobulinemia; primary endpoint of 20% MRR exceeded.

• December 11, 2024, 6:59 PM ET other material materiality 0.85 negative item 2.05item 8.01item 7.01item 9.01 ◈ Restructurings & Charges

  Cellectar pivots away from iopofosine I 131 accelerated approval; cuts workforce 60%

  Due to FDA Type-C meeting, accelerated approval for iopofosine I 131 would now require randomized confirmatory study with PFS endpoint; company seeking strategic options for this program.

• November 18, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Cellectar Q3 cash $34.3M; raised $19.4M with potential $73.3M; positive WM data supports NDA

  Cash $34.3M at Sept 30, 2024, up from $9.6M at Dec 31, 2023; raised $19.4M from warrant exercises with potential for additional $73.3M.

• November 1, 2024, 7:59 PM ET regulatory materiality 0.70 positive item 8.01item 9.01

  Cellectar regains Nasdaq compliance after filing restated financials and Form 10-Q

  Received Nasdaq letter dated Oct 31, 2024 confirming compliance with Listing Rule 5250(c)(1).

• August 23, 2024, 7:59 PM ET regulatory materiality 0.80 negative item 3.01item 7.01item 9.01

  Cellectar to restate financial statements, receives Nasdaq delinquency notice for late Q2 filing

  Restating audited FY2022 & FY2023 and unaudited Q1-Q3 2023 & Q1 2024 due to warrant accounting error in Oct 2022 financing.

• August 13, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Cellectar reports Q2 2024 cash of $25.9M; pivotal WM trial shows 80% ORR, exceeding primary endpoint

  Cash and equivalents $25.9M as of June 30, 2024, up from $9.6M at Dec 31, 2023. Net cash used in ops Q2 2024 was $14.1M.

• August 9, 2024, 7:59 PM ET other material materiality 0.85 negative item 4.02

  Cellectar restates 2022-2024 financials; warrant accounting error triggers non-reliance

  Board concludes FY2022, FY2023 audited and Q1-Q3 2023, Q1 2024 interim statements are unreliable.

• July 23, 2024, 7:59 PM ET other material materiality 0.85 positive item 2.02item 7.01item 8.01item 9.01

  Cellectar's iopofosine I 131 hits primary endpoint in WM pivotal study; 56.4% MRR

  CLOVER WaM study met primary endpoint: MRR 56.4% (95% CI 42-67%) vs 20% agreed target.

• July 22, 2024, 7:59 PM ET other material materiality 0.80 positive item 1.01item 3.02item 3.03item 7.01item 9.01

  Cellectar raises $19.4M via warrant exercise; new warrants could add $73.3M

  Gross proceeds of ~$19.4M from exercise of Tranche B warrants at reduced price of $2.52/share.

• July 11, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 4.01item 9.01

  Cellectar Biosciences dismisses Baker Tilly, hires Deloitte; cites material weaknesses

  Audit Committee dismissed Baker Tilly and is engaging Deloitte & Touche as independent auditor for FY2024, subject to standard procedures.

• May 14, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Cellectar Q1 net loss $0.74/share; cash $40M; WM study data in June

  Net loss of $21.6M ($0.74/share) in Q1 2024 vs $8.6M ($0.76/share) in Q1 2023; cash $40.0M.

• March 27, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Cellectar reports FY2023 net loss $38M; plans iopofosine NDA submission H2 2024

  Net loss $38.0M ($3.11 per share) vs $28.6M ($4.05) in prior year.

• January 25, 2024, 6:59 PM ET other material materiality 0.60 positive item 8.01

  Cellectar reports full exercise of Tranche A warrants raising $44.1M

  Tranche A warrants from September 2023 financing exercised in full.

• January 9, 2024, 6:59 PM ET other material materiality 0.90 positive item 8.01item 9.01

  Cellectar announces positive pivotal trial data for iopofosine I 131 in WM

  CLOVER-WaM study met primary endpoint with 61% major response rate (p<0.0001), exceeding 20% statistical hurdle.

• November 29, 2023, 6:59 PM ET regulatory materiality 0.75 positive item 8.01

  Cellectar regains Nasdaq compliance via $35M+ market value of listed securities

  Nasdaq notified Cellectar on Nov 21, 2023, that it meets the $35M minimum market value of listed securities under Rule 5550(b)(2), resolving the deficiency.

• November 2, 2023, 7:59 PM ET other material materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Cellectar to release top-line WM pivotal data at JP Morgan Conference week of Jan 8, 2024; raises up to $102.9M via PIPE

  Top-line data from Waldenstrom's macroglobulinemia pivotal trial to be released week of Jan 8, 2024 at JP Morgan Healthcare Conference.

• October 27, 2023, 7:59 PM ET regulatory materiality 0.60 negative item 5.03item 5.07item 8.01item 9.01 ◈ Shareholder Votes ×3◈ Governance Changes

  Cellectar shareholders approve 10M share increase; Nasdaq OKs compliance plan with Feb 12 deadline

  Shareholders approved amendment to increase authorized common stock from 160M to 170M shares at special meeting on Oct 25.

• September 8, 2023, 7:59 PM ET other material materiality 0.75 positive item 1.01item 3.02item 5.03item 9.01 ◈ Governance Changes ×3◈ Material Agreements

  Cellectar raises $24.5M via private placement of Series E-1 preferred stock and warrants

  Raised $24.5M selling 1,225 shares Series E-1 Preferred Stock at $20,000/share plus warrants for additional preferred shares.

• August 21, 2023, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

  Cellectar Biosciences receives Nasdaq delisting notice over negative stockholders' equity

  Stockholders' equity of ($467,004) as of June 30, 2023, below Nasdaq's $2.5M minimum.

• August 14, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Cellectar Q2 net loss $8.2M; cash $5.2M; WM pivotal data expected 2H23

  Net loss ($8.2M, $0.73/sh) vs ($7.4M, $1.22/sh) in Q2 2022; R&D expense $6.3M, up 40% YoY.

• June 29, 2023, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Cellectar presents iopofosine I 131 MM data: 32% ORR at optimal dose >60 mCi TAD

  Overall response rate 23% in 64 evaluable patients; 32% ORR at optimal >60 mCi TAD dose.

• June 13, 2023, 7:59 PM ET other material materiality 0.75 negative item 7.01item 8.01item 9.01

  Cellectar delays WM pivotal trial top-line data to H2 2023; pediatric glioma trial to start Q3

  Top-line data from WM CLOVER-WaM trial delayed to H2 2023; 2024 product launch still targeted.

• May 4, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Cellectar reports Q1 net loss of $8.6M; cash at $12.7M with runway into Q4 2023

  Net loss of ($8.6M) or ($0.76)/share vs ($6.1M) or ($1.00)/share in Q1 2022.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event other_material

17 positive 8 negative 25 neutral

source · CLRB on sec.gov